How well did Mannkind's stock perform in 2014?


Quick Answer

MannKind's stock price fluctuated in 2014, performing extremely well at times but dropping to less than $6 in late December, explains The Motley Fool. At one point, the stock was worth more than $11 a share, about three times the value of its lowest price of $3.80.

Continue Reading

Full Answer

MannKind shareholders had expected more in 2014, notes The Motley Fool. Afrezza, the company's top product, received Food and Drug Administration approval for diabetes type 1 and type 2 patients. However, MannKind spent a lot of money to develop Afrezza, and it may never earn enough profits to offset its deficit of nearly $2.5 billion.

Learn more about Investing

Related Questions